Tag
A landmark randomized trial demonstrates that atorvastatin reduces major cardiovascular events in adults aged 70 and older without established cardiovascular disease but does not extend disability-free survival, highlighting nuanced conside
In a secondary analysis of the randomized STOP‑CA trial, atorvastatin 40 mg daily attenuated anthracycline‑associated increases in aortic stiffness measured by CMR pulse wave velocity, suggesting vascular protection and a potential strategy
The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.
